TY - JOUR
T1 - Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer
AU - Shien, Kazuhiko
AU - Papadimitrakopoulou, Vassiliki A.
AU - Wistuba, Ignacio I.
N1 - Funding Information:
This study was supported by the Cancer Prevention Research Institute of Texas Multi-Investigator Research Award (RP120713 and RP150405), The University of Texas Lung Specialized Programs of Research Excellence grant (P50CA70907; to I.I.W.). K.S. is supported by the Japan Society for the Promotion of Science Postdoctoral Fellowships for Research Abroad.
Publisher Copyright:
© 2016 Elsevier Ireland Ltd
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Inhibitors of the programmed cell death 1 (PD-1) pathway show the potential to substantially increase the efficacy of therapy for various malignancies, including non–small cell lung cancer (NSCLC). At the same time, substantial effort has been invested in finding biomarkers predicting which patients will respond best to this immune checkpoint inhibition. PD-L1 expression in tumor cells and the tumor microenvironment, genetic alterations and mutational load in tumor cells, and pre-existing immunity and its enhancement during treatment through tumor-infiltrating immune cells have been associated with outcomes of immune checkpoint inhibition. Here, we review the reported predictive biomarkers of response to PD-1 pathway immune checkpoint inhibitors in NSCLC, mainly focusing on results obtained with clinical trials.
AB - Inhibitors of the programmed cell death 1 (PD-1) pathway show the potential to substantially increase the efficacy of therapy for various malignancies, including non–small cell lung cancer (NSCLC). At the same time, substantial effort has been invested in finding biomarkers predicting which patients will respond best to this immune checkpoint inhibition. PD-L1 expression in tumor cells and the tumor microenvironment, genetic alterations and mutational load in tumor cells, and pre-existing immunity and its enhancement during treatment through tumor-infiltrating immune cells have been associated with outcomes of immune checkpoint inhibition. Here, we review the reported predictive biomarkers of response to PD-1 pathway immune checkpoint inhibitors in NSCLC, mainly focusing on results obtained with clinical trials.
KW - Biomarker
KW - Immune checkpoint inhibition
KW - NSCLC
KW - PD-1
KW - PD-L1
UR - http://www.scopus.com/inward/record.url?scp=84977274739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84977274739&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2016.06.016
DO - 10.1016/j.lungcan.2016.06.016
M3 - Review article
C2 - 27565919
AN - SCOPUS:84977274739
SN - 0169-5002
VL - 99
SP - 79
EP - 87
JO - Lung Cancer
JF - Lung Cancer
ER -
